DE69942365D1 - Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben - Google Patents
Gezielte zufuhr von pharmazeutischen agenzien zu verletzten gewebenInfo
- Publication number
- DE69942365D1 DE69942365D1 DE69942365T DE69942365T DE69942365D1 DE 69942365 D1 DE69942365 D1 DE 69942365D1 DE 69942365 T DE69942365 T DE 69942365T DE 69942365 T DE69942365 T DE 69942365T DE 69942365 D1 DE69942365 D1 DE 69942365D1
- Authority
- DE
- Germany
- Prior art keywords
- binding domain
- fusion polypeptide
- collagen binding
- nucleic acid
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/127,134 US6387663B1 (en) | 1998-07-31 | 1998-07-31 | Targeting pharmaceutical agents to injured tissues |
PCT/US1999/017297 WO2000006195A1 (en) | 1998-07-31 | 1999-07-30 | Targeting pharmaceutical agents to injured tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69942365D1 true DE69942365D1 (de) | 2010-06-24 |
Family
ID=22428477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69942365T Expired - Lifetime DE69942365D1 (de) | 1998-07-31 | 1999-07-30 | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben |
Country Status (11)
Country | Link |
---|---|
US (2) | US6387663B1 (de) |
EP (1) | EP1100535B1 (de) |
JP (1) | JP4564657B2 (de) |
AT (1) | ATE467425T1 (de) |
AU (1) | AU758483B2 (de) |
CA (1) | CA2337979A1 (de) |
DE (1) | DE69942365D1 (de) |
ES (1) | ES2346275T3 (de) |
IL (3) | IL141141A0 (de) |
NZ (1) | NZ509804A (de) |
WO (1) | WO2000006195A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60025830T2 (de) * | 1999-07-21 | 2006-11-02 | University Of Southern California, Los Angeles | Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8460367B2 (en) | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
WO2001068158A1 (en) * | 2000-03-15 | 2001-09-20 | Orbus Medical Technologies Inc. | Coating that promotes endothelial cell adherence |
US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20040053368A1 (en) * | 2000-08-15 | 2004-03-18 | Tetsuya Ishikawa | Collagen-binding hybrid polypeptide |
WO2002030443A2 (en) * | 2000-10-11 | 2002-04-18 | The Wistar Institute | Regulation of human skin healing |
ES2186501B1 (es) * | 2000-11-23 | 2006-05-16 | Universidad De Malaga | Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno. |
US7217570B2 (en) | 2001-08-23 | 2007-05-15 | The Wistar Institute Of Anatomy And Biology | Organotypic intestinal culture and methods of use thereof |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7060684B1 (en) * | 2002-12-16 | 2006-06-13 | Quijano Rodolfo C | Device for treating diabetes and methods thereof |
WO2005003317A2 (en) * | 2003-07-01 | 2005-01-13 | Regents Of The University Of Minnesota | Engineered blood vessels |
US20090035257A1 (en) * | 2005-08-25 | 2009-02-05 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
WO2007073661A1 (fr) | 2005-12-26 | 2007-07-05 | Yantai Zhenghai Bio-Technology Co., Ltd. | Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee |
CN105327393A (zh) | 2006-06-22 | 2016-02-17 | 南佛罗里达大学 | 胶原支架、具有其的医用植入物以及使用方法 |
DE102007010306A1 (de) * | 2007-02-22 | 2008-08-28 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Bispezifisches Fusionsprotein mit therapeutischem und diagnostischem Potenzial |
ES2675174T3 (es) | 2007-04-09 | 2018-07-09 | The Board Of Trustees Of The University Of Arkansas | Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea |
JP5260976B2 (ja) * | 2008-02-08 | 2013-08-14 | 東ソー株式会社 | 血液凝固第viii因子c2ドメインタンパク質の製造方法 |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
CN101671396B (zh) * | 2008-09-11 | 2012-07-18 | 烟台正海生物技术有限公司 | 与胶原蛋白特异结合的血管内皮生长因子及其应用 |
WO2011146902A1 (en) * | 2010-05-21 | 2011-11-24 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
SG187120A1 (en) * | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
WO2012112767A2 (en) * | 2011-02-16 | 2012-08-23 | Purdue Research Foundation | Collagen-targeted nanoparticles |
EP3391899B1 (de) | 2011-12-14 | 2020-07-15 | The Board of Trustees of the University of Arkansas | Abgabe therapeutischer wirkstoffe über ein kollagenbindungsprotein |
WO2013120060A1 (en) | 2012-02-09 | 2013-08-15 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
WO2016054107A1 (en) | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
CN106188306B (zh) * | 2015-05-04 | 2020-07-24 | 北京同建再生医学技术有限公司 | 治疗性重组抗体、其编码基因及应用 |
US10040840B2 (en) | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
US10981980B2 (en) | 2016-06-15 | 2021-04-20 | Counterpoint Biomedica Llc | Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells |
JP2020501510A (ja) * | 2016-09-20 | 2020-01-23 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物 |
US10913779B2 (en) | 2017-01-25 | 2021-02-09 | Counterpoint Biomedica Llc | Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections |
US11624060B2 (en) | 2017-02-10 | 2023-04-11 | The Board Of Trustees Of The University Of Arkansas | Collagen-binding agent compositions and methods of using the same |
CN109125710A (zh) * | 2017-06-15 | 2019-01-04 | 中国科学院遗传与发育生物学研究所 | 胶原靶向血管内皮生长因子在陈旧性心肌梗死治疗中的应用 |
JP2021516966A (ja) | 2018-03-09 | 2021-07-15 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組織への生物学的薬物の送達 |
WO2020086758A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
BR112022001320A2 (pt) * | 2019-07-25 | 2022-04-12 | Univ Chicago | Composições e métodos compreendendo agentes terapêuticos ativados por protease |
CN113121700B (zh) * | 2019-12-30 | 2023-06-13 | 独步吾奇生物医疗科技(江苏)有限公司 | 与胶原特异结合的重组蛋白、其编码基因及应用 |
IL297495A (en) | 2020-04-22 | 2022-12-01 | Dragonfly Therapeutics Inc | Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins |
WO2022256568A1 (en) * | 2021-06-02 | 2022-12-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for localization of growth factors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE120206T1 (de) * | 1986-05-30 | 1995-04-15 | Scripps Clinic Res | Peptide, die die bindung des von-willebrand- faktors inhibieren. |
US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
ES2303726T3 (es) * | 1997-04-10 | 2008-08-16 | University Of Southern California | Proteinas modificadas que se fijan a componentes de la matriz extracelular. |
US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
-
1998
- 1998-07-31 US US09/127,134 patent/US6387663B1/en not_active Expired - Lifetime
-
1999
- 1999-07-30 NZ NZ509804A patent/NZ509804A/en not_active IP Right Cessation
- 1999-07-30 IL IL14114199A patent/IL141141A0/xx unknown
- 1999-07-30 AT AT99938902T patent/ATE467425T1/de not_active IP Right Cessation
- 1999-07-30 JP JP2000562049A patent/JP4564657B2/ja not_active Expired - Fee Related
- 1999-07-30 WO PCT/US1999/017297 patent/WO2000006195A1/en active Application Filing
- 1999-07-30 EP EP99938902A patent/EP1100535B1/de not_active Expired - Lifetime
- 1999-07-30 CA CA002337979A patent/CA2337979A1/en not_active Abandoned
- 1999-07-30 AU AU53286/99A patent/AU758483B2/en not_active Ceased
- 1999-07-30 DE DE69942365T patent/DE69942365D1/de not_active Expired - Lifetime
- 1999-07-30 ES ES99938902T patent/ES2346275T3/es not_active Expired - Lifetime
-
2001
- 2001-01-28 IL IL141141A patent/IL141141A/en not_active IP Right Cessation
-
2002
- 2002-04-17 US US10/125,332 patent/US6955898B2/en not_active Expired - Fee Related
-
2008
- 2008-04-10 IL IL190793A patent/IL190793A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP4564657B2 (ja) | 2010-10-20 |
ATE467425T1 (de) | 2010-05-15 |
ES2346275T3 (es) | 2010-10-13 |
EP1100535B1 (de) | 2010-05-12 |
AU758483B2 (en) | 2003-03-20 |
WO2000006195A1 (en) | 2000-02-10 |
AU5328699A (en) | 2000-02-21 |
EP1100535A1 (de) | 2001-05-23 |
EP1100535A4 (de) | 2004-12-29 |
US20020164719A1 (en) | 2002-11-07 |
JP2002521044A (ja) | 2002-07-16 |
US6387663B1 (en) | 2002-05-14 |
NZ509804A (en) | 2003-07-25 |
CA2337979A1 (en) | 2000-02-10 |
IL190793A0 (en) | 2008-11-03 |
IL141141A (en) | 2008-07-08 |
IL141141A0 (en) | 2002-02-10 |
US6955898B2 (en) | 2005-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69942365D1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
DE69834267D1 (de) | Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen | |
ATE393831T1 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
DK0910647T3 (da) | Human DNase i hyperaktive varianter | |
BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
PT923570E (pt) | Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos | |
DE69941576D1 (de) | Antisense-modulation der survivin-expression | |
ATE342067T1 (de) | Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon | |
ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
DE69934998D1 (de) | Antisense modulation der expression von integrin alpha 4 | |
EA200000378A1 (ru) | Усеченные по амино-концу мср-2 как антагонисты хемокинов | |
AR023482A1 (es) | Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos | |
DE69835680D1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
DE69534180D1 (de) | Promotor der tie rezeptor protein kinase | |
DE60025830D1 (de) | Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
IL133172A (en) | Diphosphonic acid salts for the treatment of osteoporosis | |
YU60199A (sh) | Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji | |
ATE349521T1 (de) | Mit cd40 und traf interagierende proteine | |
ATE325812T1 (de) | Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors | |
ATE362531T1 (de) | Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung | |
MX9803801A (es) | Colagena de tipo ix y quimeras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |